Table 1.
Participant demographics
| Mean (SD) or N (%) | Range | |
|---|---|---|
| Age | 56.8 (8.3) | 36.0–78.0 |
| Race | 137 (92.0%) | |
| White | 10 (6.7%) | |
| Black | 2 (1.3%) | |
| Mixed Race | ||
| BMI, kg/m2 | 27.9 (6.0) | 18.7–45.5 |
| <18.5 underweight | 0 (0%) | |
| 18.5-24.9 Healthy | 54 (36.2%) | |
| 25-29.9 Overweight | 50 (33.6%) | |
| >29.9 Obese | 45 (30.2%) | |
| Trunk fat, kg (DXA) | 15.7 (6.8) | 3.1–34.3 |
| Education | ||
| High school or less | 18 (12.1%) | |
| Some college | 25 (16.8%) | |
| College graduate | 52 (34.9%) | |
| Graduate school/professional training | 54 (36.2%) | |
| Years since treatment | 3.2 (2.3) | |
| Chemotherapy treatment | 100 (67.1%) | |
| Radiation treatment | 87 (58.4%) | |
| Current Hormone therapy | 121 (81.2%) | |
| Cancer stage | ||
| Stage I | 74 (49.7%) | |
| Stage II | 69 (46.3%) | |
| Stage III | 6 (4.0%) | |
| Any comorbidities | 18 (12.1%) | |
| PSWQ | 43.6 (12.8) | 17–76 |
| MAAS | 4.3 (0.9) | 1.4–6.0 |
SD standard deviation, BMI body mass index, PSWQ Penn State Worry Questionnaire total score, MAAS Mindful Attention & Awareness Scale total score. Comorbidities were measured using the Charlson Comorbidity Index.